AlloVir Inc. (NASDAQ:ALVR) does about 247.91K shares in volume on a normal day but saw 375500 shares change hands in Friday trading. The company now has a market cap of 631.89M USD. Its current market price is $6.94, marking an increase of 12.30% compared to the previous close of $6.18. The 52 week high reached by this stock is $10.29 whilst the lowest price level in 52 weeks is $3.17. The script in recent trading has seen the stock touch a high of $7.24 and a low of $6.14.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AlloVir Inc. (ALVR) has a 20-day trading average at $6.09 and the current price is -32.56% off the 52-week high compared with 118.93% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.86 and its 200-day simple moving average is $6.25. If we look at the stock’s price movements over the week, volatility stands at 11.02%, which decreases to 7.67% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 63.34 to suggest the stock is neutral.
4 analysts observing the AlloVir Inc. (ALVR) stock have set the 12-month price targets for the company’s shares at between $16.00 and $30.00. The consensus objective for the share price is $23.00, suggesting that the stock has a potential upside of 69.83% over the period. The median price target is 67.72% away from the current levels at $21.50.
FactSet Research has provided data showing that 4 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 4 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on October 19, 2021 when Morgan Stanley resumed the stock to “Overweight” and issued a price target of $48. Morgan Stanley initiated its price target at $49.
The current price level is 15.65%, 18.28%, and 11.29% away from its SMA20, SMA50, and SMA200 respectively, with the ALVR price moving below the 50-day SMA on February 17. AlloVir Inc. (ALVR) stock is up 12.48% over the week and 35.55% over the past month. Its price is 35.28% year-to-date and -18.83% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$0.5 above consensus estimates by $0.03. The company’s next earnings report is expected on 05/04/2023, with forecasts estimating quarterly EPS at -$0.54 and -$2.25 for whole year. ALVR’s earnings per share are forecast to grow by 17.90% this year and 5.80% over next year.
Its 12-month price target is $21.50. To reach the target analysts have set, the stock logically needs to grow 69.83 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $16.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $30.00.
Outstanding shares total 84.95M with insiders holding 49.98% of the shares and institutional holders owning 40.47% of the company’s common stock. The company has a return on equity of -91.00%. Price to book ratio is 2.33.
According to a U.S. Securities and Exchange Commission filing, ACAP Strategic Fund has added its position in AlloVir Inc. (ALVR) to 2,466,847 shares, mirroring a recent increase by 80.33%. ACAP Strategic Fund added 1.1 million shares of AlloVir Inc. common stock bringing its total worth to about $14.26 million at the end of recent close, SEC documents show. ACAP Strategic Fund isn’t the only investment manager who changed stakes and is followed by Fidelity Growth Company Fund, which sold off 14692.0 shares to end up with 2,142,978 shares worth $12.39 million.
